Spine surgeons at UC San Diego Health just turned a complex, high-stakes operation into a choreographed, data-driven performance that put the West Coast on notice. The institution’s first spine surgery using a fully integrated robotic, AI-enabled platform was more than a successful case; it was a
Ivan Kairatov brings hands‑on R&D experience in neuromuscular drug development and a clear view of how dosing, delivery, and clinic operations intersect in real life. With the MHRA authorizing a higher‑dose nusinersen regimen, he explains how two 50mg loading doses 14 days apart and 28mg
Decades of Alzheimer’s drug programs faltered because promising molecules either nudged the wrong levers of cell biology or stalled at the brain’s front door, and the result has been a cycle of costly starts and quiet sunsets that underscored how hard it is to increase autophagic clearance without
Admission to GLP-1 therapy once crawled through a maze of clinic calendars, phone tag, and insurer scripts, but a wave of purpose-built telehealth apps has turned that maze into a guided lane on a phone that now functions as both navigator and engine. The change was not merely cosmetic. Adaptive
Tiny sensors wrapped around a baby’s wrists and ankles promise to turn fleeting clinic snapshots into a living record of early motor development, offering a clearer path to timely identification and support when every month of neuroplasticity still counts. These wearables, paired with analytics,
Oxygen can sharpen the sword or feed the fire in glioblastoma therapy, and hyperbaric dosing, timing, and biology together decide which edge cuts and whether treatment harms or helps. This research summary examines how hyperbaric oxygen therapy (HBOT) might both strengthen and undermine standard
